MX2014005400A - Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent. - Google Patents

Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent.

Info

Publication number
MX2014005400A
MX2014005400A MX2014005400A MX2014005400A MX2014005400A MX 2014005400 A MX2014005400 A MX 2014005400A MX 2014005400 A MX2014005400 A MX 2014005400A MX 2014005400 A MX2014005400 A MX 2014005400A MX 2014005400 A MX2014005400 A MX 2014005400A
Authority
MX
Mexico
Prior art keywords
urate
lowering agent
halofenate
methods
gout
Prior art date
Application number
MX2014005400A
Other languages
Spanish (es)
Other versions
MX357507B (en
Inventor
Brian Edward Lavan
Gopal Chandra Saha
Brian K Roberts
Charles A Mcwherter
Original Assignee
Cymabay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics Inc filed Critical Cymabay Therapeutics Inc
Publication of MX2014005400A publication Critical patent/MX2014005400A/en
Publication of MX357507B publication Critical patent/MX357507B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Disclosed herein are pharmaceutical compositions, methods and kits for lowering the serum uric acid level of a subject and for the treatment of a condition associated with elevated serum uric acid levels comprising administering a composition comprising a first urate-lowering agent and a second urate-lowering agent. In some aspects the first urate-lowering agent is (-)- halofenate, (-)- halofenic acid, or a pharmaceutically acceptable salts thereof. In some aspects the second urate-lowering agent is an inhibitor of uric acid production, a uricosuric agent, a uricase, or a pharmaceutically acceptable salt thereof.
MX2014005400A 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent. MX357507B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059394 WO2013066349A1 (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent

Publications (2)

Publication Number Publication Date
MX2014005400A true MX2014005400A (en) 2015-02-12
MX357507B MX357507B (en) 2018-07-12

Family

ID=48192533

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005400A MX357507B (en) 2011-11-04 2011-11-04 Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent.

Country Status (13)

Country Link
EP (1) EP2773336A4 (en)
JP (1) JP6202633B2 (en)
KR (1) KR20140121383A (en)
CN (2) CN109908124A (en)
AU (1) AU2011380507B2 (en)
CA (1) CA2859686C (en)
CL (1) CL2014001155A1 (en)
IL (1) IL232386A0 (en)
MX (1) MX357507B (en)
NZ (1) NZ624708A (en)
SG (1) SG11201402032RA (en)
WO (1) WO2013066349A1 (en)
ZA (1) ZA201403575B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104602686A (en) * 2012-04-13 2015-05-06 西玛贝医药公司 Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6368756B2 (en) * 2016-10-20 2018-08-01 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Method of treating hyperuricemia in patients suffering from gout using halofenate or halofenic acid and a second uric acid lowering drug
CN108014108A (en) * 2016-11-03 2018-05-11 江苏万邦生化医药股份有限公司 The application of lesinurad or its pharmaceutically acceptable salt in the medicine for treating or preventing Cushing syndrome is prepared
WO2019082335A1 (en) * 2017-10-26 2019-05-02 大塚製薬株式会社 Inositol phosphate-containing composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
WO2011032175A1 (en) * 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto

Also Published As

Publication number Publication date
CA2859686C (en) 2018-09-11
NZ624708A (en) 2015-11-27
ZA201403575B (en) 2015-11-25
CA2859686A1 (en) 2013-05-10
CL2014001155A1 (en) 2015-01-16
AU2011380507A1 (en) 2014-05-29
KR20140121383A (en) 2014-10-15
JP6202633B2 (en) 2017-09-27
EP2773336A1 (en) 2014-09-10
EP2773336A4 (en) 2015-06-03
JP2014532758A (en) 2014-12-08
AU2011380507B2 (en) 2017-06-15
CN104066427A (en) 2014-09-24
WO2013066349A1 (en) 2013-05-10
MX357507B (en) 2018-07-12
IL232386A0 (en) 2014-06-30
SG11201402032RA (en) 2014-09-26
CN109908124A (en) 2019-06-21

Similar Documents

Publication Publication Date Title
PH12020500203A1 (en) Identification of lkb1 mutation as a predictive boimarker for sensitivity to tor kinase inhibitors
EA201100440A1 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF THEIR APPLICATION FOR CORRECTION OF URIC ACID LEVEL
JP2012184234A5 (en)
MA37400A1 (en) Cyclil compounds are not heterogeneous as mek inhibitors
EA201200793A1 (en) TREATMENT OF GENOTYPED PATIENTS WITH DIABETES DPP-4 INHIBITORS, SUCH AS LINAGLIPTIN
EA201270221A1 (en) TREATMENT OF CROWN DISEASE WITH LACQUINIMODE
BR112013014914A2 (en) compound, pharmaceutical composition, method of treating cancer in a patient and use
EA018193B3 (en) Compounds and pharmaceutical compositions for reducing uric acid level
UA107115C2 (en) Thioacetate pyridine derivatives, a composition based on them and their application
MY184914A (en) Methods of administering pirfenidone theraphy
MX351230B (en) Ophthalmic formulation and method for ameliorating presbyopia.
MX2012000275A (en) Acid pump antagonist for treatment of diseases associated with abnormal gastrointestinal movement.
MX2013002390A (en) Treatment of myocardial infarction using tgf - beta antagonists.
MY182983A (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
EA201490928A1 (en) METHODS OF TREATMENT FOR ACUTE GUTTERS
MX2012009600A (en) Methods for stabilizing joint damage in subjects using xanthine oxidoreductase inhibitors.
WO2010090494A3 (en) Medical use of 5-benzylaminosalicylic acid derivatives or salts thereof
MX2014005400A (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent.
TR201900438T4 (en) Non-acylated ghrelin fragments for use in the treatment of Prader-willi syndrome.
PH12014502282A1 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
MX2022009874A (en) Heterocyclic pad4 inhibitors.
SG195170A1 (en) Methods of treating or preventing rheumatic disease
WO2011127393A3 (en) Variants of ancestral uricases and uses thereof
IL232385A (en) Use of the compounds halofenate or halofenic acid in the manufacture of medicaments for treating hyperuricemia in patients with gout, hyperuricemia or impaired renal function
IN2012DN03387A (en)

Legal Events

Date Code Title Description
FG Grant or registration